Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.1072651
Keywords
epigenetic; DNA methylation; DNA methyltransferase; DNA methyltransferase inhibitor; tumor immunotherapy
Categories
Funding
- Technological Special Project for Significant New Drugs Development
- National Natural Science Foundation of China [2018ZX09201018-021, 2018ZX09201018-020]
- National Major Scientific and Sichuan Science and Technology Program [82073318]
- National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University [2019YFS0003]
- Post-Doctor Research Project, West China Hospital, Sichuan University [Z20201004]
- Science and Technology Project of the Health Planning Committee of Sichuan [2020HXBH020]
- Ministry of Science and Technology Project of the People's Republic of China [20PJ022]
- [2018YFC2001802-1]
Ask authors/readers for more resources
DNA methylation is an important epigenetic process that regulates gene expression and has become a promising target for cancer treatment.
DNA methylation mediated by DNA methyltransferase is an important epigenetic process that regulates gene expression in mammals, which plays a key role in silencing certain genes, such as tumor suppressor genes, in cancer, and it has become a promising therapeutic target for cancer treatment. Similar to other epigenetic targets, DNA methyltransferase can also be modulated by chemical agents. Four agents have already been approved to treat hematological cancers. In order to promote the development of a DNA methyltransferase inhibitor as an anti-tumor agent, in the current review, we discuss the relationship between DNA methylation and tumor, the anti-tumor mechanism, the research progress and pharmacological properties of DNA methyltransferase inhibitors, and the future research trend of DNA methyltransferase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
